Calcimedica Inc (CALC)

$0.63 +0.04 (6.63%)
Market Cap 9.31M
Revenue (ttm) 0.00
Net Income (ttm) -29.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.19
Volume 97,500
Avg Vol 291,684
Day's Range N/A - N/A
Shares Out 15.74M
Stochastic %K 67%
Beta 0.85
Analysts Strong Sell
Price Target $10.33

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 5500
Address:
505 Coast Boulevard South, Suite 307, La Jolla, United States
MUBSN
MUBSN May. 12 at 7:15 PM
$CALC what a pipeline!!
0 · Reply
Nousernam3
Nousernam3 May. 12 at 6:22 PM
$CALC in for a đź’Ż
0 · Reply
keokeostwiz
keokeostwiz May. 12 at 3:56 PM
$CALC Auxora P2b results establishing a strong foundation toward filling the void in AP and AKI unmet medical need areas critical in providing therapy to patients suffering from pancreatitis and kidney disease....the immediate targets for the company are FDA acceptance of P3 trial design and financing.....with positive P2b results supporting a strong clinical resume these objectives should be achieved in the second quarter setting the stage for the balance of 2026 success......JMO
1 · Reply
66Caprice327
66Caprice327 May. 12 at 11:49 AM
$CALC Let her buck…
0 · Reply
ye81
ye81 May. 12 at 11:12 AM
$CALC https://finance.yahoo.com/sectors/healthcare/articles/calcimedica-reports-first-quarter-2026-110000015.html
0 · Reply
Action80gr
Action80gr May. 12 at 9:20 AM
$CALC Severe Hantavirus cases involve hyperinflammation, vascular leak & pulmonary edema — interesting overlap with Auxora’s CRAC inhibition mechanism. Not saying pipeline expansion, but scientifically worth watching given prior ARDS/acute lung injury focus. Could this be a future platform opportunity? $CALC
0 · Reply
MUBSN
MUBSN May. 9 at 1:31 PM
$CALC
0 · Reply
MUBSN
MUBSN May. 9 at 1:30 PM
$CALC
1 · Reply
MUBSN
MUBSN May. 9 at 1:28 PM
$CALC
0 · Reply
keokeostwiz
keokeostwiz May. 8 at 8:12 PM
$CALC Only 57.5K shares traded today as very little sell pressure coupled with small appetite to hit the ask.....shares will be difficult to acquire under these conditions setting the stage for a news break and quick acceleration......next week should be interesting if ER debuts some new info as the silence here has been deafening and due a shakeup.....JMO
2 · Reply
Latest News on CALC
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

May 12, 2026, 7:00 AM EDT - 1 day ago

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica price target lowered to $10 from $20 at Oppenheimer

2026-03-05T13:27:54.000Z - 2 months ago

CalciMedica price target lowered to $10 from $20 at Oppenheimer

CalciMedica files $125M mixed securities shelf

2026-03-03T22:00:59.000Z - 2 months ago

CalciMedica files $125M mixed securities shelf

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 7:00 AM EST - 2 months ago

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica downgraded to Neutral from Buy at H.C. Wainwright

2026-01-29T11:11:18.000Z - 3 months ago

CalciMedica downgraded to Neutral from Buy at H.C. Wainwright

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Jan 28, 2026, 7:00 AM EST - 3 months ago

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:01 AM EST - 6 months ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 12, 2025, 7:00 AM EST - 6 months ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Oct 14, 2025, 7:00 AM EDT - 7 months ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 9 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2025, 7:00 AM EDT - 9 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 7:00 AM EDT - 11 months ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 25, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Jun 12, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

May 14, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 27, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Jan 14, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 9, 2024, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 8, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

CalciMedica Set to Join Russell Microcap® Index

Jul 1, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Set to Join Russell Microcap® Index

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 27, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 2 years ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 13, 2024, 4:05 PM EDT - 2 years ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Apr 24, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Mar 13, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 2 years ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 13, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 2 years ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CalciMedica Announces Private Placement of up to Approximately $55 Million

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

CalciMedica Announces Upcoming Presentations and Events in September

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Aug 9, 2023, 7:30 AM EDT - 3 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

MUBSN
MUBSN May. 12 at 7:15 PM
$CALC what a pipeline!!
0 · Reply
Nousernam3
Nousernam3 May. 12 at 6:22 PM
$CALC in for a đź’Ż
0 · Reply
keokeostwiz
keokeostwiz May. 12 at 3:56 PM
$CALC Auxora P2b results establishing a strong foundation toward filling the void in AP and AKI unmet medical need areas critical in providing therapy to patients suffering from pancreatitis and kidney disease....the immediate targets for the company are FDA acceptance of P3 trial design and financing.....with positive P2b results supporting a strong clinical resume these objectives should be achieved in the second quarter setting the stage for the balance of 2026 success......JMO
1 · Reply
66Caprice327
66Caprice327 May. 12 at 11:49 AM
$CALC Let her buck…
0 · Reply
ye81
ye81 May. 12 at 11:12 AM
$CALC https://finance.yahoo.com/sectors/healthcare/articles/calcimedica-reports-first-quarter-2026-110000015.html
0 · Reply
Action80gr
Action80gr May. 12 at 9:20 AM
$CALC Severe Hantavirus cases involve hyperinflammation, vascular leak & pulmonary edema — interesting overlap with Auxora’s CRAC inhibition mechanism. Not saying pipeline expansion, but scientifically worth watching given prior ARDS/acute lung injury focus. Could this be a future platform opportunity? $CALC
0 · Reply
MUBSN
MUBSN May. 9 at 1:31 PM
$CALC
0 · Reply
MUBSN
MUBSN May. 9 at 1:30 PM
$CALC
1 · Reply
MUBSN
MUBSN May. 9 at 1:28 PM
$CALC
0 · Reply
keokeostwiz
keokeostwiz May. 8 at 8:12 PM
$CALC Only 57.5K shares traded today as very little sell pressure coupled with small appetite to hit the ask.....shares will be difficult to acquire under these conditions setting the stage for a news break and quick acceleration......next week should be interesting if ER debuts some new info as the silence here has been deafening and due a shakeup.....JMO
2 · Reply
MUBSN
MUBSN May. 8 at 7:58 PM
$CALC Auxora as a potencial candidate for hantavirus treatment?
0 · Reply
pablo4
pablo4 May. 7 at 6:01 PM
$CALC looking pretty good on a very lousy day in biotech land....see XBI.
0 · Reply
66Caprice327
66Caprice327 May. 7 at 3:34 PM
$CALC No material news. No selling. No liquidity. Easy hold.
0 · Reply
66Caprice327
66Caprice327 May. 6 at 9:04 PM
$CALC I reiterate.
1 · Reply
keokeostwiz
keokeostwiz May. 6 at 7:20 PM
$CALC Perfect storm forming with AUXORA efficacy.....P3 design acceptance forthcoming.....FDA streamlining NDA applications....incorporating AI in processing results....all assets signaling expedited approval and much needed relief for acute pancreatitis patients....a game changer for little CALC......JMO
0 · Reply
keokeostwiz
keokeostwiz May. 5 at 5:44 PM
$CALC January price 7.20 Analyst PT 20......false safety allegations....April price .46 Analyst PT 10.....partison toward price moving toward 10 by end of the year.......JMO
0 · Reply
keokeostwiz
keokeostwiz May. 5 at 2:10 AM
$CALC Reread the P2b Auxora results and the findings were so outstanding decided to keep adding everyday this stays under .60….do not understand the price disconnect relative to exciting results…with the FDA implementing a streamlines approach to NDA approval and CALC utilizing AI in trial procedures expecting only good encouraging news as P3 proceeds…difficult to ignore the equation unfolding and can even foresee a buyer appearing on the horizon….exciting times for CALC…….JMO
1 · Reply
shoemaker74
shoemaker74 May. 4 at 2:35 PM
$CALC Nice climb, any good news?
1 · Reply
SUGONDEEZNUTS
SUGONDEEZNUTS May. 1 at 5:17 PM
$CALC 10-K/A filed yesterday.
1 · Reply
keokeostwiz
keokeostwiz May. 1 at 3:31 PM
$CALC Volume surge from 21.7 to 74.9 in 10 minutes....good to see some interest ....watching for contagion continuation today.....GL
0 · Reply
keokeostwiz
keokeostwiz Apr. 30 at 3:32 PM
$CALC Using this period of price suppression to add shares before the sand in this hour glass vanishes in a blink of an eye.....JMO
0 · Reply
Super_Marioo
Super_Marioo Apr. 30 at 3:05 PM
$CALC -unbelievable that we are still trading down here. only reason I can think of is a big whale is keeping it down and wants a direct offering down here before we pop.
1 · Reply